Oncotarget

Research Papers:

Treatment plan comparison between Tri-Co-60 magnetic-resonance image-guided radiation therapy and volumetric modulated arc therapy for prostate cancer

Jong Min Park, So-Yeon Park, Chang Heon Choi, Minsoo Chun, Jin Ho Kim and Jung-In Kim _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:91174-91184. https://doi.org/10.18632/oncotarget.20039

Metrics: PDF 483 views  |   HTML 1222 views  |   ?  


Abstract

Jong Min Park1,2,3,4, So-Yeon Park1,2,3, Chang Heon Choi1,2,3, Minsoo Chun1,2,3, Jin Ho Kim1,2,3 and Jung-In Kim1,2,3

1Department of Radiation Oncology, Seoul National University Hospital, Seoul, Republic of Korea

2Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Republic of Korea

3Biomedical Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea

4Robotics Research Laboratory for Extreme Environments, Advanced Institutes of Convergence Technology, Suwon, Republic of Korea

Correspondence to:

Jung-In Kim, email: madangin@gmail.com

Keywords: prostate cancer, magnetic-resonance image-guided radiation therapy, volumetric modulated arc therapy

Received: June 13, 2017     Accepted: July 25, 2017     Published: August 08, 2017

ABSTRACT

To investigate the plan quality of tri-Co-60 intensity-modulated radiation therapy (IMRT) with magnetic-resonance image-guided radiation therapy compared with volumetric-modulated arc therapy (VMAT) for prostate cancer. Twenty patients with intermediate-risk prostate cancer, who received radical VMAT were selected. Additional tri-Co-60 IMRT plans were generated for each patient. Both primary and boost plans were generated with tri-Co-60 IMRT and VMAT techniques. The prescription doses of the primary and boost plans were 50.4 Gy and 30.6 Gy, respectively. The primary and boost planning target volumes (PTVs) of the tri-Co-60 IMRT were generated with 3 mm margins from the primary clinical target volume (CTV, prostate + seminal vesicle) and a boost CTV (prostate), respectively. VMAT had a primary planning target volume (primary CTV + 1 cm or 2 cm margins) and a boost PTV (boost CTV + 0.7 cm margins), respectively. For both tri-Co-60 IMRT and VMAT, all the primary and boost plans were generated that 95% of the target volumes would be covered by the 100% of the prescription doses. Sum plans were generated by summation of primary and boost plans. In sum plans, the average values of V70 Gy of the bladder of tri-Co-60 IMRT vs. VMAT were 4.0% ± 3.1% vs. 10.9% ± 6.7%, (p < 0.001). Average values of V70 Gy of the rectum of tri-Co-60 IMRT vs. VMAT were 5.2% ± 1.8% vs. 19.1% ± 4.0% (p < 0.001). The doses of tri-Co-60 IMRT delivered to the bladder and rectum were smaller than those of VMAT while maintaining identical target coverage in both plans.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 20039